--- title: "Sigyn Therapeutics (SIGY) stock: news and investor profile" url: "https://aibio.space/companies/sigyn-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Sigyn Therapeutics Inc. (OTC: SIGY), United States. The directory classifies it as Pharmaceuticals: Major." --- SIGY Sigyn Therapeutics Inc. OTC · United States # Sigyn Therapeutics (SIGY) news Company Updates · 2026-05-07 ## [Oragenics signs letter of intent to license CardioDialysis for TBI](https://aibio.space/news/oragenics-signs-letter-intent-license-cardiodialysis-tbi/) Oragenics signed a non-binding letter of intent to license certain indications of CardioDialysis from Sigyn Therapeutics for traumatic brain injury. The proposed terms include 3,250,000 restricted preferred shares and a 3% royalty for six years. ## Latest Sigyn Therapeutics news 1. 2025-08-15 Distress [Sigyn Therapeutics delays quarterly report for period ended June 30, 2025](https://aibio.space/news/sigyn-therapeutics-delays-quarterly-report-period-ended-june-30-2025/) Sigyn Therapeutics filed a Form 12b-25 notice on August 15, 2025 saying it cannot file its quarterly report for the period ended June 30, 2025 on time. It promises to file no later than five days after the original due date. ## Sigyn Therapeutics at a glance - **Ticker**: SIGY - **Listing**: OTC - **Country**: United States - **Cash, Sep 30, 2025**: $85,571 ### Related companies - [Harrow](https://aibio.space/companies/harrow/) NASDAQ: HROW - [Tempest Therapeutics](https://aibio.space/companies/tempest-therapeutics/) NASDAQ: TPST - [Biofrontera](https://aibio.space/companies/biofrontera-bfri/) NASDAQ: BFRI - [Avenue Therapeutics](https://aibio.space/companies/avenue-therapeutics/) OTC: ATXI - [Metagenomi Therapeutics](https://aibio.space/companies/metagenomi-therapeutics/) NASDAQ: MGX - [Omeros](https://aibio.space/companies/omeros/) NASDAQ: OMER - [Kaleido Biosciences](https://aibio.space/companies/kaleido-biosciences/) OTC: KLDO - [Assembly Biosciences](https://aibio.space/companies/assembly-biosciences/) NASDAQ: ASMB ### Also on OTC - [Target Group](https://aibio.space/companies/target/) CBDY - [Manzo Pharmaceuticals](https://aibio.space/companies/manzo-pharmaceuticals/) MNZO - [LadRx](https://aibio.space/companies/ladrx/) LADX - [LianBio](https://aibio.space/companies/lianbio/) LIANY - [Vaccinex](https://aibio.space/companies/vaccinex/) VCNX - [QHSLab](https://aibio.space/companies/qhslab/) USAQ ## What Sigyn Therapeutics does Sigyn Therapeutics Inc. develops medical devices to treat cancer and infectious disease disorders through extracorporeal blood purification. Its lead therapeutic candidate, Sigyn Therapy, is designed to extract deadly pathogens and toxins from a patient's bloodstream while also dampening excessive immune responses associated with life-threatening infections. The text says Sigyn Therapy has been validated to extract viral pathogens, bacterial toxins including endotoxin, hepatic toxins and inflammatory cytokines from human blood plasma. The company targets untreatable viral pathogens, antibiotic-resistant bacterial infections, endotoxemia and sepsis. First-in-human studies are planned in end-stage renal disease patients with endotoxemia and concurrent inflammation. Sigyn Therapy is also proposed for xenotransplantation, in gene-edited donor pigs and in human transplant recipients, to reduce the spread of infection. In cancer, the company develops devices rather than drugs. ImmunePrep is meant to enhance immunotherapeutic antibodies, ChemoPrep to reduce tumor-derived exosomes before chemotherapy, and ChemoPure to remove off-target chemotherapy from the bloodstream. | Product or program | What it is | Stage | |---|---|---| | Sigyn Therapy | Blood purification to extract pathogens, toxins and cytokines from plasma | Pre-clinical; first-in-human studies planned | | ImmunePrep | Immobilizes therapeutic antibodies in an extracorporeal circuit to sweep out decoys | | | ChemoPrep | Reduces tumor-derived exosomes before chemotherapy administration | | | ChemoPure | Extracts off-target chemotherapy from the bloodstream to reduce toxicity | | Summarised from the company's [10-K filed Apr 15, 2025](https://www.sec.gov/Archives/edgar/data/1642159/000164117225004740/form10-k.htm). ## Sigyn Therapeutics annual financials | Line | FY2024 | FY2023 | |---|---|---| | Research and development | [$773,279](https://www.sec.gov/Archives/edgar/data/1642159/000164117225004740/) | [$798,165](https://www.sec.gov/Archives/edgar/data/1642159/000164117225004740/) | | Net income (loss) | [-$3.3 million](https://www.sec.gov/Archives/edgar/data/1642159/000164117225004740/) | [-$4.1 million](https://www.sec.gov/Archives/edgar/data/1642159/000164117225004740/) | | Cash from operations | [-$872,436](https://www.sec.gov/Archives/edgar/data/1642159/000164117225004740/) | [-$1.4 million](https://www.sec.gov/Archives/edgar/data/1642159/000164117225004740/) | | Cash and equivalents | [$12,144](https://www.sec.gov/Archives/edgar/data/1642159/000149315225023387/) | [$11,690](https://www.sec.gov/Archives/edgar/data/1642159/000164117225004740/) | Latest balance sheet, Sep 30, 2025 (10-Q): cash and equivalents $85,571. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Sigyn Therapeutics What is the ticker symbol of Sigyn Therapeutics? Sigyn Therapeutics Inc. trades under the ticker SIGY on OTC. Where is Sigyn Therapeutics listed? Sigyn Therapeutics Inc. is listed on OTC. What is the SEC CIK of Sigyn Therapeutics? The SEC Central Index Key (CIK) for Sigyn Therapeutics Inc. is 1642159. Its filings are on SEC EDGAR. How many shares does Sigyn Therapeutics have outstanding? 1,605,377 shares as of 2025-11-14, per the cover page of its 10-Q filed 2025-11-14. Which country or territory is Sigyn Therapeutics listed under? Our directory records Sigyn Therapeutics Inc. under United States. What does Sigyn Therapeutics do? Our directory classifies Sigyn Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Sigyn Therapeutics? The ISIN recorded for Sigyn Therapeutics Inc. is US82674U2050. Does aibio.space cover Sigyn Therapeutics? aibio.space lists Sigyn Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Sigyn Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Sigyn Therapeutics develop? Sigyn Therapeutics Inc. develops medical devices to treat cancer and infectious disease disorders through extracorporeal blood purification. Its lead therapeutic candidate, Sigyn Therapy, is designed to extract deadly pathogens and toxins from a patient's bloodstream while also dampening excessive immune responses associated with life-threatening infections. What is Sigyn Therapy from Sigyn Therapeutics? Sigyn Therapy: Blood purification to extract pathogens, toxins and cytokines from plasma Stage: Pre-clinical; first-in-human studies planned. What is ImmunePrep from Sigyn Therapeutics? ImmunePrep: Immobilizes therapeutic antibodies in an extracorporeal circuit to sweep out decoys Stage: Not stated. Is Sigyn Therapeutics profitable? Sigyn Therapeutics Inc. reported a net loss of $3.3 million for the fiscal year ended Dec 31, 2024, and used $872,436 of cash in operations, per its annual report to the SEC. How much does Sigyn Therapeutics spend on research and development? $773,279 in the fiscal year ended Dec 31, 2024, per its annual report. How much cash does Sigyn Therapeutics have? $85,571 in cash at Sep 30, 2025, per its 10-Q. ## Investor discussion: Sigyn Therapeutics Members talk about Sigyn Therapeutics (SIGY). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Sigyn Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-07-16 Listings Filed to end its SEC reporting. SEC Form 15-12G. [Source](https://www.sec.gov/Archives/edgar/data/1642159/000149315226033421/form15-12g.htm) 2. 2026-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1642159/000149315226014344/formnt10-k.htm) 3. 2025-08-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1642159/000164117225024221/formnt10-q.htm) 4. 2025-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1642159/000164117225010720/formnt10-q.htm) 5. 2025-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1642159/000164117225001760/formnt10-k.htm) 6. 2024-11-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1642159/000149315224046127/formnt10-q.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:SIGY on TradingView](https://www.tradingview.com/symbols/OTC-SIGY/). ## SEC filings and registration - **SEC name**: Sigyn Therapeutics, Inc. - **CIK**: 1642159 - **Industry (SIC)**: Surgical & Medical Instruments & Apparatus (3841) - **US tickers**: SIGY (OTC) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 9190 W OLYMPIC BLVD # 263, BEVERLY HILLS, CA, 90212 - **Phone**: 619-368-2000 - **Shares outstanding**: 1,605,377 as of 2025-11-14 (10-Q filed 2025-11-14) - **Former names**: Reign Resources Corp; Reign Sapphire Corp ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1642159/000149315226007574/form8-k.htm) filed 2026-02-20 - [10-Q](https://www.sec.gov/Archives/edgar/data/1642159/000149315225023387/form10-q.htm) filed 2025-11-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1642159/000164117225026704/form10-q.htm) filed 2025-09-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1642159/000164117225024303/form8-k.htm) filed 2025-08-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/1642159/000164117225011815/form10-q.htm) filed 2025-05-20 - [10-K](https://www.sec.gov/Archives/edgar/data/1642159/000164117225004740/form10-k.htm) filed 2025-04-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1642159/000149315225009462/form8-k.htm) filed 2025-03-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1642159/000149315225002575/form8-k.htm) filed 2025-01-16 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001642159), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Sigyn Therapeutics Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker SIGY, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Sigyn Therapeutics Inc. - **Ticker**: SIGY - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US82674U2050 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-SIGY/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/sigyn-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Sigyn Therapeutics (SIGY) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/sigyn-therapeutics/